In 60 patients with persistent AF, epicardial LAA closure using LARIAT was associated with persistent neurohormonal changes favoring blood pressure reduction over 2 years.
Cohort (n=60)
No
Does percutaneous epicardial left atrial appendage exclusion using LARIAT alter neurohormonal profiles in patients with long-standing, persistent atrial fibrillation?
Epicardial LAA closure is associated with persistent, long-term favorable neurohormonal changes and reductions in blood pressure in patients with persistent AF.
BACKGROUND: Recent data suggest that epicardial left atrial appendage closure (LAAC) is associated with several short-term neurohormonal effects. However, the long-term effects are currently unknown. OBJECTIVE: To investigate the effects of percutaneous epicardial left atial appendage (LAA) exclusion using LARIAT on neurohormonal profiles at long-term follow-up. METHODS: In a prospective single centre study, 60 patients with long-standing, persistent atrial fibrillation (AF) LARIAT were treated. The major hormones of the adrenergic system, renin-angiotensin-aldosterone system (RAAS), and natriuretic peptides were assessed before the intervention and at regular intervals during the following two years. RESULTS: In patients with epicardial LAAC, atrial natriuretic peptide (ANP) levels were significantly increased from baseline at 24 h and decreased at 7 days, 1 month, and 3 months, while remaining unchanged at 12 and 24 months. Noradrenaline levels were significantly lower at 24 h, 7 days, 1 month, 6 months, 12 months, and 24 months, while epinephrine levels decreased significantly at 1 month, 6 months, 12 months, and 24 months. Plasma renin activity significantly decreased at 7 days, 1 month, 6 months, 12 months, and 24 months, while aldosterone levels significantly decreased at 6 months, 12 months, and 24 months. Endothelin-1 and vasopressin showed a significant increase and decrease, respectively, at 24 h, 7 days, 1 month, 6 months, 12 months, and 24 months. There was also a significant decrease in systolic and diastolic blood pressure at 3 months, 6 months, 1 year, and 2 years after the intervention. CONCLUSIONS: Epicardial LAAC in AF patients is associated with persistent neurohormonal changes favouring blood pressure reduction.
Bartuś et al. (Wed,) conducted a cohort in Long-standing, persistent atrial fibrillation (n=60). Percutaneous epicardial left atrial appendage exclusion using LARIAT was evaluated on Neurohormonal profiles (adrenergic system, RAAS, natriuretic peptides) and blood pressure. In 60 patients with persistent AF, epicardial LAA closure using LARIAT was associated with persistent neurohormonal changes favoring blood pressure reduction over 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: